Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B

Clinical Infectious Diseases

Volumn 36, Issue 6, 2003, Pages 687-696

  Lai, Ching Lung ^a   Dienstag, Jules ^c   Schiff, Eugene ^d   Leung, Nancy W Y ^b   Atkins, Mark ^f   Hunt, Christine ^e   Brown, Nathaniel ^e   Woessner, Mary ^e   Boehme, Richard ^e   Condreay, Lynn ^e  

^a QUEEN MARY HOSPITAL   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^e GLAXOSMITHKLINE   (United States)

^f GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ASPARTIC ACID; LAMIVUDINE; METHIONINE; PLACEBO; TYROSINE; VIRUS DNA;

ABDOMINAL DISCOMFORT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BODY MASS; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; GENDER; HEADACHE; HEPATITIS B; HUMAN; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; PREVALENCE;

EID: 0037443950     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/368083     Document Type: Article

References (44)

1. Hannoun C, Horal P, Lindh M. Long-term mutation rates in the hepatitis B virus genome. J Gen Virol 2000; 81:75-83.
2. Kimberlin DYV, Whitley RJ. Antiviral resistance: mechanisms, clinical significance, and future implications. J Antimicrob Chemother 1996; 37:403-21.
3. Saag MS, Emini EA, Laskin OL, et al. A short-term clinical evaluation of L-697,661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase. N Engl J Med 1993; 329:1065-72.
4. Stanat SC, Reardon JE, Erice A, et al. Ganciclovir-resistant cytomegalovirus clinical isolates: mode of resistance to ganciclovir. Antimicrob Agents Chemother 1991; 35:2191-7.
5. Tatarowicz WA, Lurain NS, Thompson KD. A ganciclovir-resistant clinical isolate of human cytomegalovirus exhibiting cross-resistance to other DNA polymerase inhibitors. J Infect Dis 1992; 166:904-7.
6. Burns WH, Santos GW, Saral R, et al. Isolation and characterization of resistant herpes simplex virus after acyclovir therapy. Lancet 1982; 1(8269) 421-3.
7. Lai CL, Chien RN, Leung NWY, et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998; 339:61-8.
8. + lymphocyte counts and the risk of progression to AIDS. N Engl J Med 1996; 334:426-31.
9. Gauthier J, Bourne EJ, Lutz MYV, et al. Quantitation of hepatitis B viremia and emergence of YMDD variants in patients with chronic hepatitis B treated with lamivudine. J Infect Dis 1999; 180:1757-62.
10. Mason W, Litwin S. Pathogenesis of hepadnavirus infections. In: Lai CL, Locarnini S, eds. A guide to hepatitis B virus. London: International Medical Press, 2003:99-113.
11. Zoulim F. Therapy of chronic hepatitis B virus infection: inhibition of the viral polymerase and other antiviral strategies. Antiviral Res 1999; 44:1-30.
12. Gunther S, Sommer G, Plikat U, et al. Naturally occurring hepatitis B virus genomes bearing the hallmarks of retroviral G to A hypermuration. Virology 1997; 235:104-8.
13. Blum HE. Variants of hepatitis B, C, and D viruses: molecular biology and clinical signifcance. Digestion 1995; 56:85-95.
14. Bartholomew MM, Jansen RW, Jeffers LJ, et al. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997; 349:20-2.
15. Allen MI, Deslauriers M, Andrews CW, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology 1998; 27:1670-7.
16. Ling R, Harrison TJ. Functional analysis of mutations conferring lamivudine resistance on hepatitis B virus. J Gen Virol 1999; 80:601-6.
17. Melegari M, Scaglioni PP, Wands JR. Hepatitis B mutants induced by 3TC and famciclovir are replication defective. Hepatology 1998; 27:628-33.
18. Chayama K, Suzuki Y, Kobayashi M, et al. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 1998; 27:1711-6.
19. Gauthier J, Bourne EJ, Lutz MW, et al. Quantitation of hepatitis B viremia and emergence of YMDD variants in patients with chronic hepatitis B treated with lamivudine. J Infect Dis 1999; 180:1757-62.
20. Dienstag JL, SchiffER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341: 1256-63.
21. Schalm SW, Heathcote J, Cianciara J, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomized trial. Gut 2000; 46:562-8.
22. Schiff E, Karayalcin S, Grimm I, et al. A placebo controlled study of lamivudine and interferon alpha-2b in patients with chronic hepatitis B who previously failed interferon therapy [abstract 901]. Hepatology 1998; 28:388A.
23. Liaw YF, Leung NWY, Chang TT, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 2000; 119:172-80.
24. Leung N, Lai CL, Chang TT, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after three years of therapy. Hepatology 2001; 33:1527-32.
25. Allen MI, Gauthier J, DesLauriers M, et al. Two sensitive PCR-based methods for detection of hepatitis B virus variants associated with reduced susceptibility to lamivudine. J Clin Microbiol 1999; 37:3338-47.
26. Honkoop P, de Man RA, Niesters HGM, et al. Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy. Hepatology 2000; 32:635-9.
27. Schuurman R, Nijhuis M, van Leeuwen R, et al. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis 1995; 171:1411-9.
28. Perrillo RP, Rakela J, Dienstag JL, et al. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Hepatology 1999; 29:1581-6.
29. Schiff ER, Heathcote J, Dienstag JL, et al. Improvements in liver histology and cirrhosis with extended lamivudine therapy [abstract 546]. Hepatology 2000; 32:296A.
30. Leung NW, Lai CL, Guan R, Liaw YE The effect of longer duration of harbouring lamivudine-resistant hepatitis B virus (YMDD mutants) on liver histology during 3 years lamivudine in Chinese patients [abstract 706]. Hepatology 2001; 34:348A.
31. Bock C-T, Tillmann HL, Torresi J, et al. Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation. Gastroenterology 2002; 122:264-73.
32. Dienstag JL, Schiff ER, Mitchell M, et al. Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy. Hepatology 1999; 30:1082-7.
33. Liaw YF, Chien RN, Yeh CT, et al. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999; 30:567-72.
34. Buti M, Sánchez F, Cotrina M, et al. Quantitative hepatitis B virus DNA testing for the early prediction of the maintenance of response during lamivudine therapy in patients with chronic hepatitis B. J Infect Dis 2001; 183:1277-80.
35. Yuen M-F, Sablon E, Hui C-K, Yuan H-J, Decraemer H, Lai C-L. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 2001; 34:785-91.
36. Stuyver L, Locarnini S, Lok A, et al. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 2001; 33:751-7.
37. Zöllner B, Peterson J, Schröter M, et al. 20-Fold increase in risk of lamivudine resistance in hepatitis B virus subtype adw. Lancet 2001; 357:934-5.
38. Ruiz L, Valdez A, Cotrina M, et al. Three years of lamivudine in anti-HBe positive patients decreased virological and biochemical response [abstract 358]. J Hepatology 2002; 36(Suppl 1):101.
39. Tillmann HL, Trautwein C, Bock T, et al. Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under HBIg immunoglobulin after liver transplantation. Hepatology 1999; 30:244-56.
40. Perrillo RP, Wright T, Rakela J, et al. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 2001; 33:424-32.
41. Mutimer D, Pillay D, Shields P, et al. Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient. Gut 2000; 46:107-13.
42. Perrillo R, Schiff E, Yoshida E, et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000; 32:129-34.
43. Marcellin P, Chang T-T, Lim SG, et al. GS-98-437: a double-blind, randomized, placebo-controlled study of adefovir dipivoxil (ADV) for the treatment of patients with HBeAg+ chronic hepatitis B infection: 48 week results [abstract 340A]. Hepatology 2001; 34:671.
44. Peters M, Hann HW, Martin P, et al. Adefovir dipivoxil (ADV) alone and in combination with lamivudine (LAM) suppresses LAM-resistant hepatitis B virus (HBV) replication: 16 week interim analysis [abstract 13]. J Hepatology 2002; 36(Suppl 1):6.